A. Evens

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
A Evens, Andrew M Evens, Andrew Matthew Evens, A. M. Evens, A.m. Evens, A M Evens, Andy M Evens, Andrew M. Evens, Andrew Evens
Publication record
513 papers · 15,548 citations · H-index 64

PAPERS

ASTCT Clinical Practice Recommendations for Transplantation in Classical Hodgkin Lymphoma.
20250 citationsauthor #9
Real‐world evidence of the safety and survival with CD19 CAR‐T cell therapy for relapsed/refractory solid organ transplant‐related PTLD
202328 citationsauthor #17
Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers
202321 citationsauthor #46
An international real-world analysis of relapsed/refractory lymphoma occurring during pregnancy
20233 citationsauthor #18
Overall survival in classic Hodgkin lymphoma pts who progress after autologous stem cell transplant in the era of novel agents
20232 citationsauthor #3
Factors associated with health-related quality of life in a cohort of cancer survivors in New Jersey
202319 citationsauthor #12
SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).
202395 citationsauthor #6
EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort
20235 citationsauthor #50
Sociodemographic and Health Correlates of Multiple Health Behavior Adherence among Cancer Survivors: A Latent Class Analysis
20233 citationsauthor #13
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphoma
20239 citationsauthor #13
Overall survival of patients with cHL who progress after autologous stem cell transplant: results in the novel agent era
20238 citationsauthor #3
17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023.
202318 citationsauthor #6
Observations of Oncologists on Treatment Selection With Interim Positron Emission Tomography–Adapted Approaches in Classic Hodgkin Lymphoma: The Real-World CONNECT Study
20234 citationsauthor #10
CNS prophylaxis for diffuse large B-cell lymphoma.
20227 citationsauthor #8
Scaffold-mediated switching of lymphoma metabolism in culture
20226 citationsauthor #3
FLIPI-3: A New PET-Based Prognostic Index for Follicular Lymphoma Based on Results from a Validation Study with the ECOG-ACRIN E2408 Cohort
20221 citationsauthor #12
Acknowledgment of Reviewers 2021
20220 citationsauthor #42
COVID-19 perceptions, impacts, and experiences: a cross-sectional analysis among New Jersey cancer survivors
20224 citationsauthor #9
S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1
20221 citationsauthor #10
HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1.
20220 citationsauthor #10
Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma
20224 citationsauthor #42
The impact of classic Hodgkin lymphoma (cHL) on informal caregivers: Results from the cHL—Real-world observations from physicians, patients, and caregivers on the disease and its treatment (CONNECT) study.
20220 citationsauthor #2
Treatment Strategies for Advanced Classical Hodgkin Lymphoma in the Times of Dacarbazine Shortage.
20227 citationsauthor #3
Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
20221 citationsauthor #10
Identification of Genetic Subtypes in Follicular Lymphoma
20223 citationsauthor #24
First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.
202210 citationsauthor #10
Favorable Overall Survival Following First and Second Relapse of MCL with Availability of Novel Therapies: Results from the Lion Prospective Observational Registry
20220 citationsauthor #10
Survivorship transition care experiences and preparedness for survivorship among a diverse population of cancer survivors in New Jersey.
20228 citationsauthor #2
P009: Improved Overall Survival with First-Line Brentuximab Vedotin plus Chemotherapy in Patients with Advanced Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1
20220 citationsauthor #9
Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy
20222 citationsauthor #10
Development and Validation of the advanced-Stage Hodgkin Lymphoma (HL) International Prognostication Index (A-HIPI): A Report from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium
20220 citationsauthor #14
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma
202231 citationsauthor #9
P007: Comparative efficacy of the R-BEACOPP-14 and R-CHOP regimens in the treatment of patients with advanced stages of nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) with THRLBCL-like histopathological growth patterns in the tumor biopsy
20220 citationsauthor #28
Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma
202215 citationsauthor #1
Cancer Immunotherapy During Pregnancy for Relapsed Lymphoma
20220 citationsauthor #1
Weight Change Trends and Impact of Body Mass Index (BMI) on Outcomes in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma, a Retrospective Analysis from the Lymphoma Innovations Orien Network (LION) Consortium
20221 citationsauthor #8
The Advanced-Stage Hodgkin Lymphoma International Prognostic Index: Development and Validation of a Clinical Prediction Model From the HoLISTIC Consortium
202234 citationsauthor #14
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin's Lymphoma.
2022216 citationsauthor #11
End of induction positron emission tomography complete response (PET‐CR) as a surrogate for progression‐free survival in previously untreated follicular lymphoma
20223 citationsauthor #7
Poster: ABCL-051 realMIND: A Prospective, Multicenter, Observational Study of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting Second/Third-Line Therapy and Not Receiving a Stem Cell Transplant
20220 citationsauthor #9
Safety, Efficacy, and Outcomes of CD19 CAR T Cell Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD) in the Real World Setting
20220 citationsauthor #15
An Analysis of Transcriptomic Burden Identifies Biological Progression Roadmaps for Hematological Malignancies and Solid Tumors
20222 citationsauthor #6
Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy
20224 citationsauthor #29
ABCL-051 realMIND: A Prospective, Multicenter, Observational Study of Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Starting Second/Third-Line Therapy and Not Receiving a Stem Cell Transplant.
20220 citationsauthor #9
P010: Inferior Outcomes for Young Adults Treated on Advanced Stage Clinical Trials: Report from the HoLISTIC Consortium
20220 citationsauthor #14
Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis
202217 citationsauthor #8
Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.
20212 citationsauthor #13
Socioeconomic inequalities in treatment and relative survival among patients with diffuse large B-cell lymphoma: a Hong Kong population-based study
20217 citationsauthor #2
Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma
202118 citationsauthor #6
Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis
20212 citationsauthor #11
Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma.
202125 citationsauthor #21
HIV-associated Burkitt lymphoma: outcomes from a US-UK collaborative analysis.
202141 citationsauthor #3
Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma
20213 citationsauthor #1
A Multi-Institution Analysis of Relapsed Lymphoma Occurring during Pregnancy Including Pharmacokinetics with Antenatal Checkpoint Inhibitor Therapy
20210 citationsauthor #24
SARS‐CoV‐2 nosocomial infection: Real‐world results of environmental surface testing from a large tertiary cancer center
20217 citationsauthor #13
Burkitt Lymphoma International Prognostic Index.
202157 citationsauthor #49
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.
20219 citationsauthor #15
Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens
20212 citationsauthor #10
A Multi-Center Retrospective Review of COVID-19 Outcomes in Patients with Lymphoid Malignancy
20211 citationsauthor #18
The Atlas of Blood Cancer Genomes (ABCG) Project: A Comprehensive Molecular Characterization of Leukemias and Lymphomas
20210 citationsauthor #14
A Large Multicenter Real-World Evidence (RWE) Analysis of Autoimmune (AI) Diseases and Lymphoma: Histologic Associations, Disease Characteristics, Survival, and Prognostication
20210 citationsauthor #30
Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)-a Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared By Age
20213 citationsauthor #11
Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience.
20212 citationsauthor #13
OLDER PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA (PCNSL): REAL WORLD (RW) OUTCOMES OF POST‐INDUCTION THERAPY IN THE MODERN ERA
20211 citationsauthor #43
Treatment patterns for relapsed and refractory Hodgkin lymphoma in a community oncology setting
20211 citationsauthor #6
Burkitt Lymphoma
20210 citationsauthor #1
Oncogenic Integration of Nucleotide Metabolism via Fatty Acid Synthase in Non-Hodgkin Lymphoma
202112 citationsauthor #19
Real World Evidence (RWE) of Safety, Efficacy, and Outcomes of CD19 CAR-T Therapy in 20 Patients with Solid Organ Transplant (SOT)-Related Post-Transplant Lymphoproliferative Disorder (PTLD)
20213 citationsauthor #15
SURVIVAL FOLLOWING FIRST RELAPSE IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA
20210 citationsauthor #17
Outcomes of Burkitt lymphoma with central nervous system involvement: evidence from a large multicenter cohort study
202133 citationsauthor #2
Highlights in Hodgkin lymphoma from the 62nd American Society of Hematology Annual Meeting and Exposition: commentary.
20210 citationsauthor #1
Older patients (aged ≥60 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study
202154 citationsauthor #1
836P Socioeconomic inequalities in treatment and relative survival among patients with diffuse large B-cell lymphoma: A Hong Kong population-based study
20210 citationsauthor #2
A phase I/II trial of brentuximab vedotin plus rituximab as frontline therapy for patients with immunosuppression-associated CD30+ and/or EBV + lymphomas
202118 citationsauthor #13
ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis
20211 citationsauthor #26
Development and validation of a prediction model for 1-year mortality among older adults with Hodgkin Lymphoma who receive dose-intense chemotherapy.
202112 citationsauthor #4
Defining and Treating High-grade B-cell lymphoma, NOS.
202148 citationsauthor #3
Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium
20203 citationsauthor #18
Outcomes of Burkitt lymphoma (BL) managed in academic (Acad) or community (Comm) centers: real-world evidence (RWE) from 30 US sites.
20201 citationsauthor #19
Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).
20203 citationsauthor #19
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408
202018 citationsauthor #1
Current Treatment Options for Older Patients with Hodgkin Lymphoma
202012 citationsauthor #4
EBV-Positive Primary CNS Lymphomas in Older Patients: Incidence, Characteristics, Tumor Pathology, and Outcomes across a Large Multicenter Cohort
20201 citationsauthor #41
Real World (RW) Outcomes and Prognostication of Older Patients with Primary Central Nervous System Lymphoma (PCNSL) in the Contemporary Era
20201 citationsauthor #40
Genomic Ancestry in B Cell Lymphoid Malignancies
20200 citationsauthor #2
Continuum of Care for Hodgkin Lymphoma: Impact of Modern Therapy on Postacute Morbidity and Mortality.
20204 citationsauthor #1
Radiation-Based Approaches As an Alternative to Stem Cell Transplant for Relapsed/Refractory Classical Hodgkin Lymphoma: A Multicenter Retrospective Analysis
20201 citationsauthor #5
Optimizing Decision Making in Hodgkin Lymphoma
20202 citationsauthor #3
Lymphoma Occurring During Pregnancy: Current Diagnostic and Therapeutic Approaches
202011 citationsauthor #4
Burkitt Lymphoma in the Modern Era: Real World Outcomes and Prognostication Across 30 US Cancer Centers.
2020100 citationsauthor #1
Socioeconomic Inequalities in Treatment and Relative Survival Among Patients With Diffuse Large B-Cell Lymphoma in Hong Kong
20200 citationsauthor #2
How I treat advanced Hodgkin lymphoma — a global view
202010 citationsauthor #4
A systematic review of therapeutic regimens for older patients with newly diagnosed Hodgkin lymphoma
20201 citationsauthor #4
The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL).
20200 citationsauthor #20
First‐line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)‐Medicare population‐based study
202012 citationsauthor #6
A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib As Frontline Therapy for Patients with MYC-Aberrant Lymphoid Malignancies: The Daciphor Regimen
20204 citationsauthor #16
Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study
20200 citationsauthor #3
The Burkitt Lymphoma International Prognostic Index (BL-IPI)
20201 citationsauthor #49
PD-L1 Pathway Markers and Chromosome 9p24.1 Alterations in Patients with Classic Hodgkin Lymphoma Treated with Frontline Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy
20200 citationsauthor #9
ABCL-283: A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) as Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas
20200 citationsauthor #14

TIMELINE

1998 9 citations

2002 64 citations

2003 59 citations

2004 950 citations

2005 274 citations

2006 996 citations

2007 1,295 citations

2008 401 citations

2009 1,177 citations

2010 1,048 citations

2011 506 citations

2012 1,398 citations

2013 1,891 citations

2014 1,253 citations

2015 372 citations

2016 969 citations

2017 516 citations

2018 493 citations

2019 514 citations

2020 324 citations

2021 362 citations

2022 377 citations

2023 215 citations

2025 0 citations

Unknown 0 citations

A. Evens

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT